Clinical significance of preoperative neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio in the prognosis of resected early‐stage patients with non‐small cell lung cancer: A meta‐analysis

BACKGROUND Poor prognosis is linked to peripheral blood levels of preoperative platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) in many advanced cancers. Nevertheless, whether the correlation exists in resected early-stage cases with non-small cell lung cancer (NSCLC) stays controversial. Consequently, we performed a meta-analysis to explore the preoperative NLR and PLR's prognostic significance in early-stage patients with NSCLC undergoing curative surgery. METHODS Relevant studies that validated the link between preoperative NLR or PLR and survival results were found via the proceeding databases: PubMed, Embase, Cochrane Library, and Web of Science. The merged 95% confidence interval (CI) and hazard ratio (HR) was employed to validate the link between the NLR or PLR's index and overall survival (OS) and disease-free survival (DFS) in resected NSCLC cases. We used sensitivity and subgroup analyses to assess the studies' heterogeneity. RESULTS An overall of 21 studies were attributed to the meta-analysis. The findings indicated that great preoperative NLR was considerably correlated with poor DFS (HR = 1.58, 95% CI: 1.37-1.82, p < 0.001) and poor OS (HR = 1.51, 95% CI: 1.33-1.72, p < 0.001), respectively. Subgroup analyses were in line with the pooled findings. In aspect of PLR, raised PLR was indicative of inferior DFS (HR = 1.28, 95% CI: 1.04-1.58, p = 0.021) and OS (HR = 1.37, 95% CI: 1.18-1.60, p < 0.001). In the subgroup analyses between PLR and DFS, only subgroups with a sample size <300 (HR = 1.67, 95% CI: 1.15-2.43, p = 0.008) and TNM staging of mixed (I-II) (HR = 1.47, 95% CI: 1.04-2.07, p = 0.028) showed that the link between high PLR and poor DFS was significant. CONCLUSIONS Preoperative elevated NLR and PLR may act as prognostic biomarkers in resected early-stage NSCLC cases and are therefore valuable for guiding postoperative adjuvant treatment.

[1]  Q. Luo,et al.  Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection , 2021, Frontiers in Oncology.

[2]  J. Spicer,et al.  Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes. , 2021, Clinical Lung Cancer.

[3]  C. Boshoff,et al.  Toward personalized treatment approaches for non-small-cell lung cancer , 2021, Nature Medicine.

[4]  M. Masuda,et al.  Preoperative inflammation-based scores predict early recurrence after lung cancer resection , 2021, Journal of thoracic disease.

[5]  H. Hamid,et al.  Prognostic and predictive value of neutrophil-to-lymphocyte ratio after curative rectal cancer resection: A systematic review and meta-analysis. , 2021, Surgical oncology.

[6]  Jinming Yu,et al.  Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. , 2020, Future oncology.

[7]  Gengyun Sun,et al.  Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. , 2020, International immunopharmacology.

[8]  Xue Yan,et al.  Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer , 2020, Bioscience reports.

[9]  J. Watanabe,et al.  High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study , 2020, Breast Cancer.

[10]  G. Toyokawa,et al.  Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer , 2020, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[11]  G. Che,et al.  Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study , 2019, Thoracic cancer.

[12]  K. Yasufuku,et al.  Minimally invasive surgical approaches for lung cancer , 2019, Expert review of respiratory medicine.

[13]  Dae Hyun Song,et al.  Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer , 2019, British Journal of Cancer.

[14]  W. Guo,et al.  Systemic immune‐inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non‐small cell lung cancer , 2019, Thoracic cancer.

[15]  Yingwei Xue,et al.  Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells , 2019, Journal of Experimental & Clinical Cancer Research.

[16]  Liming Huang,et al.  The prognostic role of preoperative circulating neutrophil–lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis , 2018, World Journal of Urology.

[17]  Xue-wen Zhang,et al.  Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer , 2018, Cancer management and research.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  Hongdian Zhang,et al.  Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[20]  S. Jin,et al.  USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation , 2018, Oncogene.

[21]  Yunjiao Wang,et al.  The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis. , 2018, International journal of surgery.

[22]  X. Qu,et al.  An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy , 2018, BMC Cancer.

[23]  Changli Wang,et al.  Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer , 2018, Cancer biology & medicine.

[24]  S. Okada,et al.  Platelet‐to‐lymphocyte ratio predicts the prognosis of patients with non‐small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy , 2017, Thoracic cancer.

[25]  D. McMillan,et al.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis , 2017, Scientific Reports.

[26]  D. Yue,et al.  Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. , 2017, Oncology letters.

[27]  Yoshifumi Yamamoto,et al.  Prognostic role of neutrophil–lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis , 2017, PloS one.

[28]  Ning Li,et al.  Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non‐small cell lung cancer: Results from a large cohort , 2017, Thoracic cancer.

[29]  Tae Min Kim,et al.  Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  P. Shah,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis , 2017, Breast Cancer Research.

[31]  F. Pezzella,et al.  Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Matsuda,et al.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis , 2016, Annals of Surgical Oncology.

[33]  K. Shimizu,et al.  Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer , 2015, World Journal of Surgical Oncology.

[34]  M. Chenard,et al.  Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases , 2015, British Journal of Cancer.

[35]  Changli Wang,et al.  Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. , 2015, American journal of surgery.

[36]  Changli Wang,et al.  Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study , 2015, PloS one.

[37]  R. Mehran,et al.  Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study , 2015, Cancer medicine.

[38]  X. Qu,et al.  Evaluation of Preoperative Hematologic Markers as Prognostic Factors and Establishment of Novel Risk Stratification in Resected pN0 Non-Small-Cell Lung Cancer , 2014, PloS one.

[39]  S. Singhal,et al.  Neutrophils recruit regulatory T‐cells into tumors via secretion of CCL17—A new mechanism of impaired antitumor immunity , 2014, International journal of cancer.

[40]  M. Seckl,et al.  Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer , 2014, British Journal of Cancer.

[41]  D. Su,et al.  Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer , 2013, International journal of cancer.

[42]  L. Lang-Lazdunski.  Surgery for nonsmall cell lung cancer , 2013, European Respiratory Review.

[43]  C. Holmes,et al.  The platelet contribution to cancer progression , 2011, Journal of thrombosis and haemostasis : JTH.

[44]  G. E. Carpagnano,et al.  Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8 , 2011, BMC Cancer.

[45]  Y. Gong,et al.  Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model , 2010, Cell and Tissue Research.

[46]  R. Mesa,et al.  Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia , 2005, Leukemia.

[47]  S. Marcus,et al.  Activation of progelatinase A (MMP‐2) by neutrophil elastase, cathepsin G, and proteinase‐3: A role for inflammatory cells in tumor invasion and angiogenesis , 2001, Journal of cellular physiology.